ABP Transplant Hepatology common mistakes
ABP Transplant Hepatology · Understand the traps and how to avoid them.
Evaluating prolonged neonatal jaundice with a total bilirubin alone and reassuring the family when the value is only mildly elevated.
Trainees anchor on physiologic or breastfeeding jaundice and forget that conjugated hyperbilirubinemia is always pathologic; total bilirubin can look unimpressive while the direct fraction is rising.
What to do instead
Fractionate every bilirubin in an infant jaundiced beyond two weeks. Treat a direct/conjugated bilirubin >1 mg/dL or >20% of total as an urgent cholestasis evaluation: stool color history, physical exam, liver ultrasound, and timely hepatobiliary imaging or biopsy.
Requiring hepatic encephalopathy to diagnose pediatric acute liver failure, or applying adult INR thresholds without documenting vitamin K unresponsiveness.
Encephalopathy is subtle or absent in infants, and adult acute liver failure criteria do not map onto children; candidates therefore under-recognize PALF and delay transfer.
What to do instead
Apply the PALF Study Group definition: no known chronic liver disease, biochemical evidence of acute liver injury, and coagulopathy not corrected by vitamin K-INR 1.5–2.0 with encephalopathy or INR ≥2.0 regardless of encephalopathy. Assess mental status cautiously in infants and treat coagulopathy as a warning sign, not a threshold to wait for.
Excluding Wilson disease in an adolescent with Coombs-negative hemolysis and acute liver failure because the ceruloplasmin level is normal.
Ceruloplasmin is an acute-phase reactant and can be falsely normal in acute inflammation; trainees rely on it as a rule-out and miss a fatal but treatable diagnosis.
What to do instead
In unexplained adolescent liver failure with hemolysis, check 24-hour urine copper, slit-lamp examination for Kayser-Fleischer rings, low alkaline phosphatase, and liver biopsy copper if feasible. Do not wait for ceruloplasmin; start chelation or list for transplantation urgently.
Attributing an infant’s coagulopathy and rickets to vitamin K deficiency without ordering succinylacetone, missing tyrosinemia type 1.
Tyrosinemia is rare and tyrosine/methionine levels may be only mildly abnormal; the coagulopathy mimics vitamin K deficiency and liver failure dominates the picture.
What to do instead
Order succinylacetone whenever an infant has unexplained liver failure, coagulopathy, or rickets. Confirm the diagnosis, start nitisinone and a phenylalanine/tyrosine-restricted diet immediately, and evaluate for transplantation if liver failure is advanced.
Not screening for hepatopulmonary syndrome in a child with cirrhosis and new hypoxemia, or accepting a normal chest radiograph as reassuring.
HPS is under-recognized in children; platypnea-orthodeoxia, clubbing, and cyanosis are subtle, and trainees attribute dyspnea to ascites or pneumonia.
What to do instead
Obtain an arterial blood gas and contrast (bubble) echocardiography in any child with cirrhosis and unexplained hypoxemia or exercise intolerance. Recognize intrapulmonary shunting and evaluate for transplantation, because HPS can progress rapidly.
Managing pediatric variceal hemorrhage with fixed adult doses of octreotide or beta-blockers, or deferring airway protection in a child with hematemesis and altered mental status.
Pediatric drug dosing is weight-based and adult algorithms are memorized more thoroughly; trainees also underestimate aspiration risk during active hematemesis.
What to do instead
Give octreotide as a 1 mcg/kg bolus (maximum 50 mcg) followed by 1 mcg/kg/hour, start antibiotic prophylaxis, transfuse to a restrictive hemoglobin target, and intubate early for airway protection when mental status is impaired or bleeding is massive.
Calculating PELD with adult MELD components or omitting growth failure and age younger than 1 year, and not knowing pediatric status 1A/1B criteria.
Allocation rules are memorized from adult hepatology; pediatric exceptions and the PELD variables are tested less often and are easy to conflate with MELD.
What to do instead
Memorize PELD: age <1 year, albumin, bilirubin, INR, and growth failure (<−2 SD). Children ≥12 years use MELD. Know status 1A criteria (PALF, primary nonfunction, hepatic artery thrombosis) and the pediatric exception pathways rather than extrapolating adult rules.
Diagnosing early post-transplant graft dysfunction as cellular rejection and giving steroid pulses before obtaining Doppler ultrasound and biliary imaging.
Rejection is over-represented in teaching, while vascular thrombosis and anastomotic biliary strictures are common mimics; trainees anchor on the biopsy they expect rather than the anatomy they must exclude.
What to do instead
In any early post-transplant liver enzyme rise or fever, first obtain Doppler ultrasound of the hepatic artery and portal vein and evaluate the biliary anastomosis. Proceed to biopsy only after vascular and biliary causes are excluded or addressed; treat rejection with confirmed histology.
Interpreting a low tacrolimus trough as nonadherence without checking sampling time, drug interactions, or gastrointestinal malabsorption.
Nonadherence is a common transplant narrative, so trainees stop at that explanation; they forget that azole antifungals raise levels, rifampin lowers them, and short gut or diarrhea impairs absorption.
What to do instead
Confirm the trough was drawn 12 hours after the dose, review interacting medications, and assess for diarrhea, short bowel, or cystic fibrosis. If absorption is unreliable, change to IV or extended-release tacrolimus rather than escalating oral doses or labeling the family nonadherent.
Missing Epstein-Barr virus–driven post-transplant lymphoproliferative disorder in a child with fever, adenopathy, or tonsillar enlargement, and continuing full immunosuppression while awaiting biopsy.
PTLD presents nonspecifically and is uncommon; trainees focus on infection and rejection and do not connect EBV serostatus, immunosuppression burden, and lymphadenopathy.
What to do instead
Check EBV PCR and obtain imaging or tissue biopsy when lymphadenopathy, fever, or tonsillar hypertrophy persists. Reduce immunosuppression promptly as the first therapeutic step, then coordinate with oncology for rituximab or chemotherapy based on histology and staging.